ASLAN's Downsized US IPO Off To A Slump Start
Singapore venture ASLAN's US IPO has got off to a disappointing start, with the shares in what was already a downsized offering falling sharply in early trading.
You may also be interested in...
Singapore-based company prioritizes resources and cuts jobs following the recent Phase II failure of its lead pipeline asset in first-line gastric cancer.
The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.